Supporting the Development of Drugs for Rare Diseases - The Importance of Regulatory Transparency
N Engl J Med
.
2025 Mar 6;392(10):939-941.
doi: 10.1056/NEJMp2413309.
Epub 2025 Mar 1.
Authors
Sanket S Dhruva
1
2
3
,
Hans-Georg Eichler
4
,
Steven K Galson
5
Affiliations
1
Section of Cardiology, Department of Medicine, University of California, San Francisco, School of Medicine, San Francisco.
2
Philip R. Lee Institute for Health Policy Studies, University of California, San Francisco, San Francisco.
3
San Francisco Veterans Affairs Health Care System, San Francisco.
4
Federation of Austrian Social Insurances, Vienna.
5
Boston Consulting Group, Los Angeles, CA.
PMID:
40029202
DOI:
10.1056/NEJMp2413309
No abstract available